Company Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials.
The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.
It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Ian Smith |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 430 8200 |
| Website | stoketherapeutics.com |
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| Employer ID | 47-1144582 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian F. Smith A.C.A., C.P.A. | Interim Chief Executive Officer and Director |
| Dr. Arthur O. Tzianabos Ph.D. | Interim Executive Chairman |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder and Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Dr. Edward M. Kaye M.D., Ph.D. | Advisor and Director |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
| Isabel Aznarez Ph.D. | Co-Founder, Head of Research and Senior Vice President |
| Doug Snow | Director of Communications and Investor Relations |
| Jonathan Allan J.D. | Corporate Secretary and General Counsel |
| Dawn Kalmar | Chief Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 15, 2025 | SCHEDULE 13G/A | Filing |
| Jul 11, 2025 | EFFECT | Notice of Effectiveness |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 9, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 9, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 1, 2025 | 144 | Filing |
| Jun 26, 2025 | DRS | [Cover] Draft Registration Statement |
| Jun 23, 2025 | SCHEDULE 13D/A | Filing |
| Jun 6, 2025 | SCHEDULE 13D/A | Filing |